The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion

Structure

Volumn 7, Issue 2, 1999, Pages 111-118

  Sharp, Allan M ^a   Stein, Penelope E ^b   Pannu, Navraj S ^b   Carrell, Robin W ^b   Berkenpas, Mitchell B ^c   Ginsburg, David ^d   Lawrence, Daniel A ^e   Read, Randy J ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c PFIZER INC   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e HOLLAND LABORATORY   (United States)

Author keywords

Metastable state; Plasminogen activator inhibitor 1; Serpin; Structure based drug design

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; SERINE PROTEINASE INHIBITOR;

ARTICLE; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN STABILITY;

EID: 0033081498     PISSN: 09692126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-2126(99)80018-5     Document Type: Article

References (42)

1. 1. Wiman, B. (1995). Plasminogen activator inhibitor-1 (PAI-1) in plasma: its role in thrombotic disease. Thromb, Haem. 74, 71-76.
2. 2. Bell, W.R. (1996). The fibrinolytic system in neoplasia. Sem. Thromb. Hemost. 22, 459-478.
3. 3. Lawrence, D.A., et al., & Shore, J.D. (1995). Serpin-protease complexes are trapped as stable acyl-enzyme intermediates. J. Biol. Chem. 270, 25309-25312.
4. 4. Wilczynska, M., Fa, M., Ohlsson, P.-I. & Ny, T. (1995). The inhibition mechanism of serpins: evidence that the mobile reactive center loop is cleaved in the native protease - inhibitor complex. J. Biol. Chem. 270, 29652-29655.
5. 1-proteinase inhibitor: crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function. J. Mol. Biol. 177, 531 -556.
6. 6. Mottonen, J., et al., & Goldsmith, E.J. (1992). Structural basis of latency in plasminogen activator inhibitor-1. Nature 370, 270-273.
7. 7. Carrell, R.W., Evans, D.L. & Stein, P.E. (1991). Mobile reactive centre of serpins and the control of thrombosis. Nature 353, 576-578.
8. 1-antitrypsin. J. Biol. Chem. 270, 5282-5288.
9. 9. Beauchamp, N.J., et al., & Carrell, R.W. (1998). Antithrombins wibble and wobble (T85M/K): archetypal conformational diseases with in vivo latent-transition, thrombosis, and heparin activation. Blood, 92, 2696-2706.
10. 10. Declerck, P.J., et al., & Collen, D. (1988). Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma: identification as a multimeric form of S protein (vitronectin). J. Biol. Chem. 263, 15454-15461.
11. 11. Berkenpas, M.B., Lawrence, D.A. & Ginsburg, D. (1995). Molecular evolution of plasminogen activator inhibitor-1 functional stability. EMBO J. 14, 2969-2977.
12. 12. Aertgeerts, K., DeBondt, H.L., DeRanter, C.J. & Declerck, P.J. (1995). Mechanisms contributing to the conformational and functional flexibility of plasminogen activator inhibitor-1. Nat. Struct. Biol. 2, 891-897.
13. 13. Xue, Y., et al., & Deinum, J. (1998). Interfering with the inhibitory mechanism of serpins: crystal structure of a complex formed between cleaved plasminogen activator inhibitor type 1 and a reactive-centre loop peptide. Structure 6, 627-636.
14. 14. Wei, A., Rubin, H., Cooperman, B.S. & Christianson, D.W. (1994). Crystal structure of an uncleaved serpin reveals the conformation of an inhibitory reactive loop. Nat. Struct. Biol. 1, 251-258.
15. 15. Schreuder, H.A., et al., & Hol, W.G.J. (1994). The intact and cleaved human antithrombin III complex as a model for serpin-proteinase interactions. Nat. Struct. Biol. 1, 48-54.
16. 16. Carrell, R.W., Stein, P.E., Fermi, G. & Wardell, M.R. (1994). Biological implications of a 3 Å structure of dimeric antithrombin. Structure 2, 257-270.
17. 1-antitrypsin. Nat. Struct. Biol. 3, 676-681.
18. 18. Stein, P.E. & Carrell, R.W. (1995). What do dysfunctional serpins tell us about molecular mobility and disease? Nat. Struct. Biol. 2, 96-113.
19. 1-antitrypsin accumulation in the liver. Nature 357, 605-607.
20. 20. Eldering, E., Verpy, E., Roem, D., Meo, T. & Tosi, M. (1995). COOH-terminal substitutions in the serpin C1 inhibitor that cause loop overinsertion and subsequent multimerization. J. Biol. Chem. 270, 2579-2587.
21. 21. Carrell, R.W. & Stein, P.E. (1996). The biostructural pathology of the serpins: critical function of sheet opening mechanism. Biol. Chem. Hoppe-Seyler 377, 1-17.
22. 22. Tucker, H.M., Mottonen, J., Goldsmith, E.J. & Gerard, R.D. (1995). Engineering of plasminogen activator inhibitor-1 to reduce the rate of latency transition. War. Struct. Biol. 2, 442-445.
23. 23. Lawrence, D.A, et al., & Ginsburg, D. (1997). Characterization of the binding of different conformational forms of plasminogen activator inhibitor-1 to vitronectin: implications for the regulation of pericellular proteolysis. J. Biol. Chem. 272, 7676-7680.
24. 24. Stefansson, S., et al., & Lawrence, D.A. (1998). Plasminogen activator inhibitor-1 contains a cryptic high affinity binding site for the low density lipoprotein receptor related protein. J. Biol. Chem. 273, 6358-6366.
25. 3 binding to vitronectin. Nature 383, 441-443.
26. 26. Deng, G., Curriden, S.A., Wang, S., Rosenberg, S. & Loskutoff, D.J. (1996). Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J. Cell Biol. 134, 1563-1571.
27. 27. Preissner, K.T., May, A.E., Wohn, K.D., Germer, M. & Kanse, S.M. (1997). Molecular crosstalk between adhesion receptors and proteolytic cascades in vascular remodelling. Thromb. Haem. 78, 88-95.
28. 28. Bajou, K., et al., & Foidart, J.M. (1998). Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat. Med. 4, 923-928.
29. 29. Lawrence, D.A., Berkenpas, M.B., Palaniappan, S. & Ginsburg, D. (1994). Localization of vitronectin binding domain in plasminogen activator inhibitor-1. J. Biol. Chem. 269, 15223-15228.
30. 30. Björquist, P., et al., & Deinum, J. (1998). Identification of the binding site for a low-molecular-weight inhibitor of plasminogen activator inhibitor type 1 by site-directed mutagenesis. Biochemistry 37, 1227-1234.
31. 1-antitrypsin is in the canonical inhibitory conformation. J. Mol. Biol. 275, 419-425.
32. 32. Howard, A.J., Gilliland, G.L., Finzel, B.C., Poulos, T.L., Ohlendorf, D.H. & Salemme, F.R. (1987). The use of an imaging proportional counter in macromolecular crystallography. J. Appl. Crystallogr. 20, 383-387.
33. 33. Navaza, J. (1994). AMoRe: an automated package for molecular replacement. Acta Crystallogr. A 50, 157-163.
34. 34. Brünger, A.T. (1993). X-PLOR Version 3.1: A System for X-ray Crystallography and NMR. Yale University Press, New Haven, CT, USA.
35. 35. Brünger, A.T., et al., & Warren, G.L. (1998). Crystallography and NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr. D 54, 905-921.
36. 36. Pannu, N.S. & Read, R.J. (1996). Improved structure refinement through maximum likelihood. Acta Crystallogr. A 52, 659-668.
37. 37. Jiang, J.S. & Brünger, A.T. (1994). Protein hydration observed by X-ray diffraction: solvation properties of penicillopepsin and neuraminidase crystal structures. J. Mol. Biol, 243, 100-115.
38. 38. Jones, T.A., Zou, J.-Y., Cowan, S.W. & Kjeldgaard, M. (1991). Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A 47, 110-119.
39. 39. Vellieux, F.M.D.A.P., Hunt, J.F., Roy, S. & Read, R.J. (1995). DEMON/ANGEL: a suite of programs to carry out density modification. J. Appl. Crystallogr. 28, 347-351.
40. 40. Kraulis, P.J. (1991). MOLSCRIPT: aprogram to produce both detailed and schematic plots of protein structure. J. Appl. Crystallogr. 24, 946-950.
41. 41. McRee, D.E. (1993). Practical Protein Crystallography. Academic Press, San Diego, CA, USA.
42. 42. Stein, P. & Chothia, C. (1991 ). Serpin tertiary structure transformation. J. Mol. Biol. 221, 615-621.